Optogenetics is an exciting new technology in which viral gene or cell
delivery is used to inscribe light sensitivity in excitable tissue to enable
optical control of bioelectric behavior. Initial progress in the fledgling
domain of cardiac optogenetics has included in vitro expression
of various light-sensitive proteins in cell monolayers and transgenic animals to
demonstrate an array of potentially useful applications, including light-based
pacing, silencing of spontaneous activity, and spiral wave termination. In
parallel to these developments, the cardiac modeling community has developed a
versatile computational framework capable of realistically simulating
optogenetics in biophysically detailed, patient-specific representations of the
human heart, enabling the exploration of potential clinical applications in a
predictive virtual platform. Towards the ultimate goal of assessing the
feasibility and potential impact of optogenetics-based therapies in
cardiovascular medicine, this review provides (1) a detailed synopsis of in vivo, in
vitro, and in silico developments in the field and
(2) a critical assessment of how
existing clinical technology for gene/cell delivery and intra-cardiac
illumination could be harnessed to achieve such lofty goals as light-based
arrhythmia termination.